Histogenics Corporation (HSGX) Receiving Somewhat Favorable News Coverage, Report Finds
News articles about Histogenics Corporation (NASDAQ:HSGX) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Histogenics Corporation earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.388041679258 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
HSGX has been the topic of several analyst reports. ValuEngine raised shares of Histogenics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Zacks Investment Research lowered shares of Histogenics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. HC Wainwright set a $4.00 price target on shares of Histogenics Corporation and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 price target on shares of Histogenics Corporation in a research report on Friday, August 11th.
Shares of Histogenics Corporation (NASDAQ:HSGX) traded up 0.46% during trading on Friday, hitting $2.19. 92,171 shares of the stock traded hands. The stock has a 50 day moving average price of $1.94 and a 200-day moving average price of $1.79. Histogenics Corporation has a 1-year low of $1.45 and a 1-year high of $3.17. The stock’s market cap is $49.25 million.
Histogenics Corporation (NASDAQ:HSGX) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.06. During the same period in the prior year, the firm earned ($0.61) EPS. Equities analysts forecast that Histogenics Corporation will post ($1.09) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Histogenics Corporation (HSGX) Receiving Somewhat Favorable News Coverage, Report Finds” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/histogenics-corporation-hsgx-receiving-somewhat-favorable-news-coverage-report-finds/1616294.html.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.